Publication date:
23 February 2016
This regulatory impact statement analyses the options available for regulating the NBOMe family of hallucinogens. The preferred option involves an amendment to include the substances commonly known as 25B-NBOMe, 25C-NBOMe and 25I-NBOMe in Part 1 of Schedule 2 of the Misuse of Drugs Act 1975.
